Work

Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC)

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.7137

Authors: R. S. Keresztes, M. Socinski, P. Bonomi, A. Chen, L. Hart, R. Lilenbaum

Institutions: University of North Carolina at Chapel Hill, Cornell University, Mount Sinai Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2242889721

Cites:

Cited by: 8

Related to: 10